In light of recent media coverage surrounding the availability of weight loss medication on the NHS—particularly Tirzepatide (marketed as Mounjaro)—we want to provide clarity for our patients.
At present, we are not able to prescribe Tirzepatide, as we are still awaiting formal guidance from the Lancashire and South Cumbria Integrated Care Board (LSCICB) regarding the rollout of a new specialist weight management service.
You can find more detailed information from the LSCICB in the link below.
When this service becomes available, access to treatment will be limited to patients who meet specific clinical criteria, including:
- A Body Mass Index (BMI) of 40 kg/m² or more, or 37.5 kg/m² or more for individuals from minority ethnic backgrounds
- And The presence of at least four of the following long-term health conditions:
-Non-diabetic hyperglycaemia or Type 2 diabetes
-Hypertension (high blood pressure)
-Dyslipidaemia (abnormal cholesterol levels)
-Established cardiovascular disease
-Obstructive sleep apnoea (with a formal diagnosis)
We understand that many patients may be eager to explore new treatment options for weight management, and we will continue to keep you updated as more information becomes available.
Thank you for your understanding and patience.
Lancashire and South Cumbria ICB
Specialist weight management support in Lancashire and South Cumbria (June 2025) PDF